BAMCO Inc
RARE icon

BAMCO Inc’s Ultragenyx Pharmaceutical RARE Stock Holding History

BAMCO Inc’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-40,000
Closed -$1.68M – 334
2024
Q4 		$1.68M Sell
40,000
-8,000
-17% -$397K ﹤0.01% 281
2024
Q3 		$2.67M Buy
+48,000
New +$2.45M 0.01% 284
2017
Q2 		– Sell
-30,848
Closed -$2.09M – 347
2017
Q1 		$2.09M Buy
30,848
+1,807
+6% +$138K 0.01% 262
2016
Q4 		$2.04M Buy
+29,041
New +$2.06M 0.01% 248

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BAMCO Inc's RARE Position: Q1 2025 in Review

BAMCO Inc sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2025, closing a stake of 40,000 shares — an estimated $1.68M sold.

BAMCO Inc first reported a position in RARE in Q4 2016 and held it in 4 quarters. The position peaked at $2.67M in Q3 2024. 300 funds tracked by Wall St. Rank hold RARE as of Q1 2025.

  • BAMCO Inc reported no remaining Ultragenyx Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • BAMCO Inc sold 40,000 Ultragenyx Pharmaceutical shares in Q1 2025, an estimated $1.68M.
  • BAMCO Inc first reported a position in Ultragenyx Pharmaceutical in Q4 2016 and held it in 4 quarters.
  • BAMCO Inc's Ultragenyx Pharmaceutical position peaked at $2.67M in Q3 2024.
  • 300 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2025.

Based on BAMCO Inc's 13F filing for Q1 2025, filed 15 May 2025.